Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension

Colloids and Surfaces B: Biointerfaces

Volumn 83, Issue 2, 2011, Pages 189-197

  Wang, Yancai ^a   Liu, Zhaoping ^a   Zhang, Dianrui ^a   Gao, Xihui ^a   Zhang, Xiaoyu ^a   Duan, Cunxian ^a   Jia, Lejiao ^a   Feng, Feifei ^a   Huang, Yaojian ^b   Shen, Yuemao ^a   Zhang, Qiang ^c  

^a SHANDONG UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Cancer therapy; Deacety mycoepoxydiene; Delivery system; Dissolution velocity; Nanosuspension

Indexed keywords

AFM; ANTI-CANCER AGENTS; CANCER THERAPY; CRYSTALLINE STATE; DELIVERY SYSTEMS; DISSOLUTION PROFILES; DRY POWDERS; HIGH PRESSURE HOMOGENIZATION; IN-VITRO; IN-VITRO DISSOLUTION; IN-VITRO EVALUATION; MEAN PARTICLE SIZE; MYCOEPOXYDIENE; NANO-SUSPENSIONS; OPTICAL MICROSCOPES; PHOMOPSIS SP; PHYSICOCHEMICAL CHARACTERISTICS; POLYDISPERSITY INDICES; PROSTATE CANCERS; SATURATION SOLUBILITY; SEM; SURFACE AREA; TEM; WEAK ACIDS; XRD; ZETA POTENTIAL MEASUREMENTS;

CRYSTALLINE MATERIALS; ENZYME INHIBITION; ONCOLOGY; OPTICAL CORRELATION; PHOTON CORRELATION SPECTROSCOPY; POLYDISPERSITY; SOLUBILITY; ZETA POTENTIAL;

DISSOLUTION;

ANTINEOPLASTIC AGENT; DEACETY MYCOEPOXYDIENE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; CANCER CELL CULTURE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; DRY POWDER; FREEZE DRYING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MELTING POINT; MOLECULAR WEIGHT; NANOPHARMACEUTICS; NANOSUSPENSION; OPTICAL ROTATION; PARTICLE SIZE; PH; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; POWDER; PRIORITY JOURNAL; PROSTATE CANCER; SCANNING ELECTRON MICROSCOPY; SUSPENSION; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; EPOXY COMPOUNDS; HUMANS; MALE; MOLECULAR CONFORMATION; NANOSTRUCTURES; PARTICLE SIZE; PYRONES; SOLUBILITY; TUMOR CELLS, CULTURED;

PHOMOPSIS;

EID: 78651430460     PISSN: 09277765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2010.10.029     Document Type: Article

References (35)

1. Hecq J., Deleers M., Fanara D., Vranckx H., Boulanger P., Le Lamer S., Amighi K. Eur. J. Pharm. Biopharm. 2006, 64:360-368.
2. Io T., Fukami T., Yamamoto K., Suzuki T., Xu J.D., Tomono K., Ramamoorthy A. Mol. Pharmaceut. 2010, 7:299-305.
3. Van Eerdenbrugh B., Van den Mooter G., Augustijns P. Int. J. Pharm. 2008, 364:64-75.
4. Jacobs C., Muller R.H. Pharm. Res. 2002, 19:189-194.
5. Rabinow B.E. Nat. Rev. Drug Discovery 2004, 3:785-796.
6. Wang Y., Zhang D., Liu Z., Liu G., Duan C., Jia L., Feng F., Zhang X., Shi Y., Zhang Q. Nanotechnology 2010, 21:155104.
7. Gao L., Zhang D.R., Chen M.H., Duan C.X., Dai W.T., Jia L.J., Zhao W.F. Int. J. Pharm. 2008, 355:321-327.
8. Ganta S., Paxton J.W., Baguley B.C., Garg S. Int. J. Pharm. 2009, 367:179-186.
9. Wong J., Brugger A., Khare A., Chaubal M., Papadopoulos P., Rabinow B., Kipp J., Ning J. Adv. Drug Deliv. Rev. 2008, 60:939-954.
10. Kocbek P., Baumgartner S., Kristl J. Int. J. Pharm. 2006, 312:179-186.
11. Mauludin R., Muller R.H., Keck C.M. Int. J. Pharm. 2009, 370:202-209.
12. Keck C.M., Muller R.H. Eur. J. Pharm. Biopharm. 2006, 62:3-16.
13. Lai F., Sinico C., Ennas G., Marongiu F., Marongiu G., Fadda A.M. Int. J. Pharm. 2009, 373:124-132.
14. Van Eerdenbrugh B., Froyen L., Van Humbeeck J., Martens J.A., Augustijns P., Van Den Mooter G. Eur. J. Pharm. Sci. 2008, 35:344-353.
15. Van Eerdenbrugh B., Froyen L., Van Humbeeck J., Martens J.A., Augustijns P., Van den Mooter G. Eur. J. Pharm. Sci. 2008, 35:127-135.
16. Mauludin R., Muller R.H., Keck C.M. Eur. J. Pharm. Sci. 2009, 36:502-510.
17. Hecq J., Deleers M., Fanara D., Vranckx H., Amighi K. Int. J. Pharm. 2005, 299:167-177.
18. Teeranachaideekul V., Junyaprasert V.B., Souto E.B., Muller R.H. Int. J. Pharm. 2008, 354:227-234.
19. Hanafy A., Spahn-Langguth H., Vergnault G., Grenier P., Grozdanis M.T., Lenhardt T., Langguth P. Adv. Drug Deliv. Rev. 2007, 59:419-426.
20. Ali H.S., York P., Blagden N. Int. J. Pharm. 2009, 375:107-113.
21. Douroumis D., Fahr A. Eur. J. Pharm. Sci. 2007, 30:367-374.
22. Patravale V.B., Date A.A., Kulkarni R.M. J. Pharm. Pharmacol. 2004, 56:827-840.
23. Gramdorf S., Hermann S., Hentschel A., Schrader K., Muller R.H., Kumpugdee-Vollrath M., Kraume M. Colloids Surf. A 2008, 331:108-113.
24. Aboofazeli R., Barlow D., Lawrence M.J. AAPS PharmSci. 2000, 2:U175-U188.
25. Oguchi T., Sakai K., Sakai H., Abe M. Colloids Surf. B: Biointerfaces 2010, 79:205-209.
26. Saxena V., Sadoqi M., Shao J. Int. J. Pharm. 2004, 278:293-301.
27. Moschwitzer J., Muller R.H. Eur. J. Pharm. Biopharm. 2006, 62:282-287.
28. Muller R.H., Jacobs C., Kayser O. Adv. Drug Deliv. Rev. 2001, 47:3-19.
29. Chaubal M.V., Popescu C. Pharm. Res.-Dord. 2008, 25:2302-2308.
30. Dai W.G., Dong L.C., Song Y.Q. Int. J. Pharm. 2007, 342:201-207.
31. Fakes M.G., Vakkalagadda B.J., Qian F., Desikan S., Gandhi R.B., Lai C.J., Hsieh A., Franchini M.K., Toale H., Brown J. Int. J. Pharm. 2009, 370:167-174.
32. Muller R.H., Peters K. Int. J. Pharm. 1998, 160:229-237.
33. Junghanns J.U.A.H., Muller R.H. Int. J. Nanomed. 2008, 3:295-309.
34. Pu X., Sun J., Wang Y., Liu X., Zhang P., Tang X., Pan W., Han J., He Z. Int. J. Pharm. 2009, 379:167-173.
35. Yallapu M.M., Jaggi M., Chauhan S.C. Colloids Surf. B: Biointerfaces 2010, 79:113-125.